Hyperdiploid ALL, the most common subtype, accounting for up to 25% of pediatric ALL cases, responds well to methotrexate treatment, partly due to increased expression of the SLC19A1 gene involved in folate transport [30]. The gene discussed is SLC19A1; the disease is acute lymphoblastic leukemia.